The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives
Over the past three decades, the enhanced permeability and retention (EPR) effect has
been considered the basis of tumor-targeted drug delivery. Various cancer nanomedicines …
been considered the basis of tumor-targeted drug delivery. Various cancer nanomedicines …
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Many efforts have been made to achieve targeted delivery of anticancer drugs to enhance
their efficacy and to reduce their adverse effects. These efforts include the development of …
their efficacy and to reduce their adverse effects. These efforts include the development of …
[HTML][HTML] Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Successfully translating anti-cancer nanomedicines from pre-clinical proof of concept to
demonstration of therapeutic value in the clinic is challenging. Having made significant …
demonstration of therapeutic value in the clinic is challenging. Having made significant …
Meta-analysis of nanoparticle delivery to tumors using a physiologically based pharmacokinetic modeling and simulation approach
Numerous studies have engineered nanoparticles with different physicochemical properties
to enhance the delivery efficiency to solid tumors, yet the mean and median delivery …
to enhance the delivery efficiency to solid tumors, yet the mean and median delivery …
[HTML][HTML] The past, present, and future of breast cancer models for nanomedicine development
P Boix-Montesinos, PM Soriano-Teruel… - Advanced drug delivery …, 2021 - Elsevier
Even given recent advances in nanomedicine development of breast cancer treatment in
recent years and promising results in pre-clinical models, cancer nanomedicines often fail at …
recent years and promising results in pre-clinical models, cancer nanomedicines often fail at …
[HTML][HTML] A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer
Triple-negative breast cancer (TNBC) has few therapeutic options, and alternative
approaches are urgently needed. Stimulator of IFN genes (STING) is becoming an exciting …
approaches are urgently needed. Stimulator of IFN genes (STING) is becoming an exciting …
Chemokines in triple-negative breast cancer heterogeneity: new challenges for clinical implications
Tumor heterogeneity is a hallmark of cancer and one of the primary causes of resistance to
therapies. Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast …
therapies. Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast …
Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors
Nanoparticle based delivery formulations have become a leading delivery strategy for
cancer imaging and therapy. The success of nanoparticle-based therapy relies heavily on …
cancer imaging and therapy. The success of nanoparticle-based therapy relies heavily on …
The binding site barrier elicited by tumor-associated fibroblasts interferes disposition of nanoparticles in stroma-vessel type tumors
The binding site barrier (BSB) was originally proposed to describe the binding behavior of
antibodies to cells peripheral to blood vessels, preventing their further penetration into the …
antibodies to cells peripheral to blood vessels, preventing their further penetration into the …
A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity
The poor solubility of paclitaxel (PTX), the commercially most successful anticancer drug,
has long been hampering the development of suitable formulations. Here, we present …
has long been hampering the development of suitable formulations. Here, we present …